oking for a fair settlement offer.
http://www.glofin.comhere is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe
) offer cash advances against all types of Personal Injury & Worker Compensation claims. It works like this: Global Financial will review
d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations.
Combination pro
the merits of an applicant’s legal claim and determine the chance & size of a financial recovery. They then offer the claimant a small pe
ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc
centage of the total value of their claim in return for an assignment of a portion of the potential future proceeds in the claim. If there
easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi
is no financial recovery from the claim then the funding company receives nothing. This makes lawsuit loans very risky and actually a ven
nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically
ure capital investment rather than an actual loan as the names suggests.
The fees charge by lawsuit loan companies can vary dramatically b
and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ
ut it is usually best to stick with the larger companies, like Global Financial because they work on larger volumes and lower pricing. Usu
ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi
lly a funding company will charge either a monthly fee or a flat fee depending on the risk associate with the claim.
It is my personal opi
ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it.
Following aspects would a
nion that a claimant should ask themselves one question before applying for a cash advance against their pending claim. Will the advance t
dd to the challenges in developing combination products:
Which markets to tap where the combination products can do fairly well?
Which combination prod
at I receive pay immediate and necessary living expense? If the answer is yes then you should accept a cash advance and continue with your
cts are meaningful and rational?
Which therapeutic categories to select?
Which Combinations can address unmet needs of the patients?
Do combin
legal claim. If the answer is no then it might be wise to hold off and wait before applying for a lawsuit loan or cash advance against yo
tions increase the patient compliance?
What would be the developing cost?
How to tackle the risks encountered during combination product developmen
r pending claim. In addition, a lawsuit loan may be a very important tool when the defendant’s insurance carrier decides to make a low bal
t?
As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel
l offer for settlement in the claim. You can then use a lawsuit loan as a financial tool to say no to the low ball offer and have the fina
ping new procedures for reviewing their safety, efficacy and quality.
Professional from academic institutions, pharmaceutical industries, health care indust
cial strength to wait for a higher and fairer settlement.
Lawsuit Loans have been trademarked by Global Financial as "Lawsuit Insurance" b
y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products
ecause they offer insurance like protection to plaintiffs in the event that their claim is unsuccessful. If a plaintiff takes a cash advan
.
As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de
e against their pending legal claim and their claim is unsuccessful then they get to keep the money that was advanced to them. Thus the ca
elopment. They need to be wiser in analyzing the market trends and the regulatory requirements.
Companies that provide selfless information through particip
sh advance guarantees that their claim will be financially successful either by way of the cash advance or by way of settlement or judgment
tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products
